Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Capecitabine and Cetuximab in Rectal Cancer
NCT00297128Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Oct 2005
- Primary completion
- Aug 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in rectal cancer, sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Feasibility and tolerance of preoperative therapy. Started Oct 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00297128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297128.